Veliparib added onto frontline chemotherapy followed by veliparib maintenance monotherapy (veliparib throughout) significantly prolonged progression-free survival (PFS) in women with newly diagnosed high-grade serous ovarian carcinoma, the phase III placebo-controlled VELIA/GOG-3005 trial has shown.
Circulating tumour DNA (ctDNA) holds strong prognostic value in colorectal cancer patients, according to a new study presented at the 2019 Congress of the European Society of Medical Oncology (ESMO 2019). CtDNA may also help determine the optimum treatment intensity.
Pembrolizumab, used in both neoadjuvant and adjuvant settings, significantly improves pathological complete response (pCR) in patients with early triple-negative breast cancer (TNBC), according to late-breaking results of the phase III KEYNOTE-522 trial presented at the European Society for Medical Oncology (ESMO) Congress 2019.
The use and choice of chemotherapy significantly impact overall survival (OS) of patients with sarcoma, according to a population-based retrospective cohort study involving more than 3,000 patients treated in Hong Kong.
Obesity does not appear to be strongly correlated with an increased risk for febrile neutropaenia during levofloxacin prophylaxis in patients with haematological malignancies receiving intermediate-risk myelosuppressive chemotherapy, suggests a study.
Initiation or switch to the single-tablet regimen of bictegravir/emtricitabine/tenofovir alafenamide (TAF) led to low HIV-1 RNA viral load in people living with HIV (PLHIV), according to the BICSTaR study presented at HIV Glasgow 2020.
Use of corticosteroids appears to be an effective treatment for paediatric drug reaction with eosinophilia and systemic symptoms (DRESS), suggest the results of a recent study. In severe cases, corticosteroids used in conjunction with intravenous immunoglobulin result in fast clinical improvement.